Bioventus

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bioventus reports Q4 revenue decline, focuses on operational efficiency

Bioventus faced revenue challenges in Q4 2022 but demonstrated strength in key segments like Surgical Solutions and international growth.
Actions taken to enhance earnings and financial stability show a commitment to improving performance and regaining investor confidence.
Challenges around revenue decline, gross margin impact, and uncertainty require strategic focus on debt management and operational efficiency.

Bioventus reports Q1 revenue growth, addresses market challenges and opportunities

Bioventus delivered solid Q1 performance with revenue growth and improved EBITDA.
Challenges in the HA market and potential divestitures were key discussion points.
Opportunities lie in revenue growth strategies, cost management, and portfolio optimization.
Overall, Bioventus aims to leverage strengths for sustained growth and profitability.

Bioventus reports Q2 growth, eyes talent acquisition for future

Bioventus showcased financial achievements in Q2 2023, with a focus on improving execution, profitability, and reducing leverage.
Despite revenue decline, the company's adjusted EBITDA increased, driven by strong volume growth in pain treatments and international segment expansion.
Management's confidence in the product portfolio, growth prospects, and talent acquisition bodes well for Bioventus's future performance and strategic direction.

Bioventus reports Q3 resilience, eyes growth in international markets

Bioventus showcased resilience with strong performance in key segments despite revenue decline.
The company's strategic focus on growth drivers and international expansion bodes well for future prospects.
Challenges in certain segments are being addressed with plans for improvement and return to growth.
2024 plans emphasize investments in sales, R&D, and portfolio optimization for sustained growth.

Bioventus reports robust Q4 earnings, sets ambitious goals for 2024

Bioventus delivered strong financial performance in Q4 2023 and outlined ambitious goals for 2024.
The company's focus on revenue growth, operational efficiency, and cash flow improvement reflects a strategic approach to value creation.
While facing debt leverage challenges, Bioventus aims to leverage its strengths and opportunities to drive sustainable growth.
Investors should monitor Bioventus' progress in executing its 2024 priorities and achieving the set financial targets.

Bioventus excels in Q1 2024, focuses on growth and profitability

Bioventus demonstrated robust performance in Q1 2024, driven by revenue growth and margin improvement.
While facing challenges in international growth and operational areas, the company remains optimistic about long-term prospects.
Management's strategic priorities and financial achievements position Bioventus well for future growth and profitability.
Analyst inquiries highlighted key areas for improvement and strategic focus for Bioventus moving forward.

Bioventus excels in Q2 2024, focuses on core growth

Bioventus reported a strong Q2 2024 with revenue growth, improved profitability, and strategic divestment decision
The company aims to drive double-digit revenue and EBITDA growth for the rest of 2024 and into 2025
Despite challenges in Restorative Therapies sales, Bioventus remains focused on core segments for growth
Enhanced financial guidance and operational efficiency position Bioventus for continued success and expansion

Bioventus posts strong Q3 results, eyes growth in medical solutions

Bioventus (BVS) reported robust Q3 results with revenue growth, improved EBITDA, and positive cash flow, reflecting operational strength and financial stability.
Strategic initiatives like the sale of the rehabilitation business demonstrate a focus on optimizing the portfolio and enhancing shareholder value.
While challenges exist in Q4 growth and business transitions, Bioventus remains well-positioned to leverage opportunities in high-demand medical solutions and international markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022.

Bioventus Appoints Mark Singleton as Chief Financial Officer

DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter and fiscal year 2021 before the market opens on Thursday, March 10, 2022. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022

DURHAM, N.C., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary revenue results for the fourth quarter and full-year 2021.

Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue

DURHAM, N.C., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference via webcast on Wednesday, January 12, 2022, at 5:15 p.m. ET.

Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference

DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022.

Bioventus Appoints Michelle McMurry-Heath to Board of Directors

DURHAM, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's neXus® BoneScalpel® Access™ handpiece. The BoneScalpel Access handpiece is powered by the neXus Ultrasonic Surgical Aspirator System, a next-generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm resulting in more power, versatility, and control. The neXus system combines all the features of soft and hard (e.g. bone) tissue removal into a single fully integrated offering.

Bioventus Receives US FDA Clearance for BoneScalpel® Access™

MEMPHIS, Tenn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has signed a lease agreement to double its current operations and manufacturing space and relocate from its current facility in suburban Memphis. Bioventus expects to move its 116 employees into the new space in early Q3 of 2022 and add another 40 jobs in the next five years.

Bioventus to Expand Operations and Manufacturing in Memphis

DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today announced that Greg Anglum is transitioning from his role as Senior Vice President and Chief Financial Officer (CFO) to pursue other career opportunities. To ensure a smooth transition, Mr. Anglum will remain in his current role until a successor is named.

Bioventus Announces Chief Financial Officer Transition Plan

Bioventus Inc. (BVS) CEO Ken Reali on Q3 2021 Results - Earnings Call Transcript

DURHAM, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three and nine months ended October 2, 2021.

Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance

DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Sharon Klugewicz as Senior Vice President, Quality and Regulatory Affairs. In this role, she will be responsible for all regulatory and quality functions globally, facilitating strong alignment across commercial, operations and R&D teams.

Sharon Klugewicz Joins Bioventus as Senior Vice President, Quality and Regulatory Affairs

DURHAM, N.C., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock. Pursuant to the terms of the merger agreement, Misonix has become a wholly owned subsidiary of Bioventus.

Bioventus Completes the Acquisition of Misonix

DURHAM, N.C., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Tuesday, November 9, 2021.

Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021, by and among Bioventus, Misonix and other parties thereto, pursuant to which Misonix will be acquired by, and become a wholly-owned subsidiary of, Bioventus (the “Merger Agreement”) and the stockholders of Misonix have approved the proposal to adopt the Merger Agreement.

Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus

DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the “Election Deadline”) for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus (“Merger Sub I”), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus (“Merger Sub II”), pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of July 29, 2021, by and among Bioventus, Merger Sub I, Merger Sub II and Misonix (the “Mergers”). If the Election Deadline is delayed or extended for any reason, Bioventus and Misonix will promptly announce the delay and, when determined, the rescheduled Election Deadline.

BIOVENTUS INC. and MISONIX, INC.

Alpine Immune Sciences

I-Mab

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

3 Small Biotech Stocks in Focus on World Arthritis Day

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc., (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in innovations for active healing, announced that the American Academy of Orthopaedic Surgeons (AAOS) recently released updated clinical practice guidelines (CPG) indicating that high molecular weight cross-linked hyaluronic treatments, including Bioventus treatment DUROLANE, showed statistically significant improvement in certain knee osteoarthritis (OA) patients.  The recommendation follows a review of 28 studies assessing intra-articular hyaluronic acid (HA) injections when compared to controls.

DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons

DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has elected to make a $50 million escrow payment pursuant to its Option and Equity Purchase Agreement with CartiHeal Ltd., signaling its intent to move forward with an acquisition of CartiHeal. The Company's decision came following its review of a statistical analysis report of the pivotal clinical trial of the Agili™-C implant, reimbursement coding analysis and significant market diligence including surgeon interviews with respect to Agili-C's commercialization opportunity and ultimate market potential.

Bioventus Proceeds with Option Structure Agreement with CartiHeal

Bioventus Also Agrees to OUS Distribution and Co-Development Relationships Bioventus Also Agrees to OUS Distribution and Co-Development Relationships

Bioventus Invests in Trice Medical Minimally Invasive Technologies

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice President, Investor Relations and Treasurer. Crawford has more than 20 years of experience across multiple areas of finance and comes to Bioventus from Avanos Medical, Inc. where he served for nearly seven years as its Vice President Treasurer, Investor Relations and Financial Planning and Analysis.

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

Hill-Rom Hlds

BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On August 6, HillRom (NYSE: HRC) completed the acquisition of SV's portfolio company Bardy Diagnostics ("BDx"). In 2016, SV partnered with founder Dr. Gust Bardy to support the commercial launch of the Carnation Ambulatory Monitor, a best-in-class ambulatory cardiac monitor.

SV Health Investors Announces Three Realizations in its Growth Equity Portfolio

Maybe the equivalent of an extra full quarter of revenue will get the attention of investors.

Will a Powerful Acquisition Make This Early 2021 IPO a Buy?

Bioventus Inc. (BVS) CEO Ken Reali on Q2 2021 Results - Earnings Call Transcript

Misonix

NEW YORK, July 30, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Misonix, Inc. ("Misonix" or the "Company") (NASDAQ: MSON) in connection with the proposed cash-and-stock acquisition of the Company by Bioventus Inc. ("Bioventus") (NASDAQ: BVS). Under the terms of the merger agreement, Misonix shareholders may elect to receive either (i) 1.6839 shares of Bioventus stock, representing implied per-share merger consideration of approximately $29.05 based upon Bioventus's July 29, 2021 closing price of $17.25, or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration based on an aggregate maximum cash amount payable by Bioventus equal to $10.50 per share of Misonix stock outstanding shortly prior to the completion of the transaction.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Misonix, Inc.

Recently listed Bioventus Inc (NASDAQ: BVS) has agreed to acquire Misonix Inc (NASDAQ: MSON) for $518 million in a cash-and-stock transaction. Misonix stockholders may elect to receive either 1.6839 Bioventus shares or $28.00 in cash in the transaction.

News for Bioventus Stock (BVS)